留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

ERCC1对晚期非小细胞肺癌一线含铂化疗疗效的预测价值

宁晓红 王毓洲 孙昭 李霁 周艳萍 白春梅

宁晓红, 王毓洲, 孙昭, 李霁, 周艳萍, 白春梅. ERCC1对晚期非小细胞肺癌一线含铂化疗疗效的预测价值[J]. 协和医学杂志, 2010, 1(2): 155-159.
引用本文: 宁晓红, 王毓洲, 孙昭, 李霁, 周艳萍, 白春梅. ERCC1对晚期非小细胞肺癌一线含铂化疗疗效的预测价值[J]. 协和医学杂志, 2010, 1(2): 155-159.
Xiao-hong NING, Yu-zhou WANG, Zhao SUN, Ji LI, Yan-ping ZHOU, Chun-mei BAI. Role of ERCC1 Expression in Predicting the Outcome of Platinum-based Chemotherapy in Patients with End-stage Non-small-cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2010, 1(2): 155-159.
Citation: Xiao-hong NING, Yu-zhou WANG, Zhao SUN, Ji LI, Yan-ping ZHOU, Chun-mei BAI. Role of ERCC1 Expression in Predicting the Outcome of Platinum-based Chemotherapy in Patients with End-stage Non-small-cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2010, 1(2): 155-159.

ERCC1对晚期非小细胞肺癌一线含铂化疗疗效的预测价值

详细信息
    通讯作者:

    王毓洲 电话:010-88068315, E-mail:wangyuzhou@hotmail.com

  • 中图分类号: R734.2

Role of ERCC1 Expression in Predicting the Outcome of Platinum-based Chemotherapy in Patients with End-stage Non-small-cell Lung Cancer

More Information
  • 摘要:   目的  探讨肺癌组织ERCC1(excision repair cross-complementation group1)表达水平对晚期非小细胞肺癌含铂化疗疗效及生存期的预测价值。  方法  采用免疫组织化学方法对39例非小细胞肺癌患者的石蜡包埋肿瘤标本进行ERCC1检测, 分析其与化疗反应率及生存期间的关系。  结果  56.4%(22/39)的肿瘤组织呈ERCC1高表达。ERCC1表达与患者性别、年龄、病理类型、肿瘤分化程度、吸烟史及吸烟指数均无相关性; ERCC1低表达患者对含铂一线化疗的反应率优于ERCC1高表达者, P < 0.05。但ERCC1表达水平对患者总生存(overall survival, OS)和疾病进展(time to progression, TTP)时间没有明显影响。  结论  ERCC1在肺癌组织的表达水平可能成为预测晚期非小细胞肺癌患者一线含铂化疗方案疗效的因素之一。
  • 图  1  ERCC 1的免疫组织化学反应× 60

    A.正常组织; B.晚期非小细胞肺癌组织, 胞核中可见棕黄色颗粒沉着

    图  2  ERCC1表达水平对晚期非小细胞肺癌患者生存期的影响

    图  3  ERCC1表达水平对晚期非小细胞肺癌患者疾病进展时间的影响

    表  1  ERCC1表达与晚期非小细胞肺癌患者临床特征的关系

  • [1] Schiller JH, Harrington D, Belani CP, et al.Eastern Cooperative Oncology Group.Comparison of four chemotherapy regimens for advanced non small cell lung cancer[J]. N Engl J Med, 2002, 346:92-98. doi:  10.1056/NEJMoa011954
    [2] Soria JC.ERCC1-tailored chemotherapy in lung cancer:the first prospective randomized trial[J]. J Clin Oncol, 2007, 25:2648-2649. doi:  10.1200/JCO.2007.11.3167
    [3] Hwang IG, Ahn MJ, Park BB, et al.ERCC1 expression as a prognostic markerin N2 (+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy[J]. Cancer, 2008, 113:1379-1386. doi:  10.1002/cncr.23693
    [4] Azuma K, Sasada T, Kawahara A, et al. Expression of ERCC1 and class Ⅲ beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel[J]. Lung Cancer, 2009, 64:326-333. doi:  10.1016/j.lungcan.2008.09.002
    [5] Chen S, Zhang J, Wang R, et al.The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis[J]. Lung Cancer, 2010-06-9 [Epubaheadofprint]. http://www.cancer.gov/cancertopics/types/lung.
    [6] Reynolds C, Obasaju C, Schell MJ, et al.Randomized phase Ⅲ trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer[J]. J Clin Oncol, 2009, 27:5808-5815. doi:  10.1200/JCO.2009.21.9766
    [7] Vilmar AC, Santoni-Rugiu E, Srensen JB.ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase Ⅲ trial[J]. Ann Oncol, 2010, 21:1817-1824. doi:  10.1093/annonc/mdq053
    [8] Planchard D, Domont J, Taranchon E, et al.The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma[J]. Ann Oncol, 2009, 20:1257-1263. doi:  10.1093/annonc/mdn785
    [9] Shimizu J, Horio Y, Osada H, et al.mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines[J]. Respirology, 2008, 13: 510-517. doi:  10.1111/j.1440-1843.2008.01302.x
    [10] Booton R, Ward T, Ashcroft L, et al.ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.J Thorac Oncol, 2007, 2:902-906. doi:  10.1097/JTO.0b013e318155a637
    [11] Lee KH, Min HS, Han SW, et al.ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer[J]. Lung Cancer, 2008, 60:401- 407. doi:  10.1016/j.lungcan.2007.10.014
    [12] Su C, Zhou S, Zhang L, et al.ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical out come of advanced non-small cell lung cancer[J]. Med Oncol, 2010- 05-14 [Epubaheadofprint]. http://www.springer.com/medicine/oncology/journal/12032.
    [13] Yin J, Vogel U, Guo L, et al.Lack of association between DNA repair gene ERCC1 polymorphism and risk of lung cancer in a Chinese population[J]. Cancer Genet Cytogenet, 2006, 164:66-70. doi:  10.1016/j.cancergencyto.2005.07.003
    [14] Yin Z, Su M, Li X, et al.ERCC2, ERCC1 polymorphisms and haplotypes, cooking oil fume and lung adenocarcinoma risk in Chinese non-smoking females[J]. J Exp Clin Cancer Res, 2009, 28:153. doi:  10.1186/1756-9966-28-153
  • 加载中
图(3) / 表(1)
计量
  • 文章访问数:  307
  • HTML全文浏览量:  110
  • PDF下载量:  15
  • 被引次数: 0
出版历程
  • 收稿日期:  2010-08-23
  • 刊出日期:  2010-10-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!